Fulcrum Therapeutics (FULC) Change in Account Payables (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Change in Account Payables of $858000.0 for Q1 2026, up 150.15% year-over-year from $343000.0 in Q1 2025, and up 177.65% quarter-over-quarter from -$1.1 million in Q4 2025.
Fulcrum Therapeutics (FULC) Change in Account Payables (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Change in Account Payables data on file, last reported at $858000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $858000.0, up 150.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $943000.0 (up 140.13% YoY), and the FY2025 annual result was $428000.0, up 126.87% from the prior year.
- Change in Account Payables improved to $858000.0 in Q1 2026 per FULC's latest filing, from -$1.1 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.1 million in Q1 2024 and troughed at -$2.7 million in Q4 2024.
- A 5-year average of -$137411.8 and a median of $163000.0 in 2023 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 1150.0% in 2024 and fell as far as 279.75% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $903000.0 in 2022, then plunged by 190.48% to -$817000.0 in 2023, then sank by 230.11% to -$2.7 million in 2024, then jumped by 59.03% to -$1.1 million in 2025, then surged by 177.65% to $858000.0 in 2026.
- Business Quant data shows FULC's Change in Account Payables at $858000.0 in Q1 2026, -$1.1 million in Q4 2025, and $946000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | 858,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 858,000.00 |
| Mar 31, 2026 | 858,000.00 |
| Dec 31, 2025 | -1.11 Mn |
| Dec 31, 2025 | -1.11 Mn |
| Sep 30, 2025 | 946,000.00 |
| Sep 30, 2025 | 946,000.00 |
| Jun 30, 2025 | 244,000.00 |
| Jun 30, 2025 | 244,000.00 |
| Mar 31, 2025 | 343,000.00 |
| Mar 31, 2025 | 343,000.00 |
| Dec 31, 2024 | -2.70 Mn |
| Dec 31, 2024 | -2.70 Mn |
| Sep 30, 2024 | 297,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Jun 30, 2024 | -293,000.00 |
| Jun 30, 2024 | -293,000.00 |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | -817,000.00 |
| Dec 31, 2023 | -817,000.00 |